Stock listing
NASDAQ:IVVD Invivyd, Inc. Stock
Home listing (NASDAQ) of Invivyd, Inc.
Follow Invivyd, Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:IVVD
$0.413 USD -0.058 (-12.3%)
Close on Nov 20, 2026
- Day range
- $0.413 – $0.467 USDNov 20, 2026
- Volume
- 5.30M sharesNov 20, 2026
- Market cap
- $122.0M USDAt the close on Nov 20, 2026 · price × 295.6M shares outstanding
- 52-week range
- $0.413 – $3.010 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $4.05M USDMedian day 4.23M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:IVVD · Home | $0.413 USD | -0.058 (-12.3%) | 5,296,603 | $0.440 | $0.467 | $0.413 | $0.471 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:IVVD · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $0.413 | -0.058 | -12.3% | $0.440 | $0.467 | $0.413 | 5,296,603 | |
| $0.471 | -0.042 | -8.2% | $0.506 | $0.520 | $0.465 | 6,706,811 | |
| $0.513 | -0.025 | -4.7% | $0.545 | $0.556 | $0.490 | 6,755,504 | |
| $0.538 | -0.044 | -7.6% | $0.575 | $0.585 | $0.520 | 3,279,698 | |
| $0.582 | +0.015 | +2.6% | $0.574 | $0.589 | $0.540 | 3,155,033 | |
| $0.567 | -0.032 | -5.3% | $0.587 | $0.600 | $0.551 | 2,602,791 | |
| $0.599 | +0.025 | +4.3% | $0.591 | $0.610 | $0.580 | 1,719,196 | |
| $0.574 | -0.022 | -3.7% | $0.574 | $0.606 | $0.555 | 2,867,660 | |
| $0.596 | +0.033 | +5.9% | $0.562 | $0.614 | $0.550 | 2,911,763 | |
| $0.563 | -0.022 | -3.8% | $0.591 | $0.595 | $0.560 | 2,335,444 | |
| $0.585 | -0.049 | -7.7% | $0.635 | $0.640 | $0.556 | 4,550,658 | |
| $0.634 | +0.052 | +9.0% | $0.610 | $0.640 | $0.603 | 4,434,486 | |
| $0.582 | 0.000 | -0.1% | $0.601 | $0.620 | $0.558 | 9,316,999 | |
| $0.582 | +0.000 | +0.1% | $0.598 | $0.600 | $0.550 | 4,424,059 | |
| $0.582 | -0.020 | -3.4% | $0.562 | $0.594 | $0.538 | 5,361,494 | |
| $0.602 | -0.015 | -2.4% | $0.610 | $0.635 | $0.573 | 3,081,726 | |
| $0.617 | +0.028 | +4.7% | $0.589 | $0.626 | $0.577 | 2,895,195 | |
| $0.589 | 0.000 | -0.1% | $0.600 | $0.607 | $0.580 | 4,248,537 | |
| $0.589 | -0.024 | -3.9% | $0.630 | $0.630 | $0.581 | 2,827,018 | |
| $0.613 | +0.003 | +0.5% | $0.592 | $0.621 | $0.580 | 2,762,894 | |
| $0.610 | -0.029 | -4.6% | $0.644 | $0.663 | $0.589 | 4,317,151 | |
| $0.639 | +0.003 | +0.4% | $0.660 | $0.690 | $0.635 | 6,022,757 | |
| $0.637 | +0.027 | +4.4% | $0.622 | $0.651 | $0.617 | 2,273,319 | |
| $0.610 | -0.009 | -1.5% | $0.640 | $0.679 | $0.610 | 4,484,895 | |
| $0.619 | -0.050 | -7.5% | $0.670 | $0.680 | $0.611 | 3,450,500 | |
| $0.669 | +0.061 | +10.0% | $0.619 | $0.682 | $0.614 | 3,285,300 | |
| $0.608 | -0.038 | -5.9% | $0.640 | $0.640 | $0.601 | 3,999,700 | |
| $0.646 | -0.027 | -4.1% | $0.660 | $0.673 | $0.640 | 3,657,067 | |
| $0.673 | -0.048 | -6.6% | $0.710 | $0.717 | $0.663 | 2,825,203 | |
| $0.721 | +0.021 | +3.0% | $0.700 | $0.738 | $0.691 | 2,765,900 | |
| $0.700 | -0.029 | -4.0% | $0.740 | $0.740 | $0.670 | 10,440,900 | |
| $0.729 | -0.077 | -9.6% | $0.804 | $0.820 | $0.725 | 9,468,300 | |
| $0.806 | -0.033 | -3.9% | $0.852 | $0.854 | $0.800 | 5,048,800 | |
| $0.839 | +0.017 | +2.1% | $0.820 | $0.845 | $0.790 | 5,422,400 | |
| $0.822 | +0.005 | +0.6% | $0.835 | $0.844 | $0.770 | 7,129,000 | |
| $0.817 | -0.053 | -6.1% | $0.865 | $0.898 | $0.806 | 5,459,800 | |
| $0.870 | +0.020 | +2.4% | $0.855 | $0.879 | $0.821 | 8,385,700 | |
| $0.850 | -0.100 | -10.5% | $0.921 | $0.934 | $0.774 | 31,292,500 | |
| $0.950 | +0.016 | +1.7% | $0.976 | $1.010 | $0.940 | 11,005,200 | |
| $0.934 | +0.021 | +2.3% | $0.921 | $0.947 | $0.901 | 3,489,300 | |
| $0.913 | -0.010 | -1.1% | $0.950 | $0.970 | $0.890 | 6,000,000 | |
| $0.923 | -0.041 | -4.3% | $0.950 | $0.965 | $0.911 | 6,910,200 | |
| $0.964 | -0.056 | -5.5% | $1.010 | $1.010 | $0.910 | 8,439,300 | |
| $1.020 | +0.265 | +35.1% | $0.835 | $1.050 | $0.820 | 15,009,500 | |
| $0.755 | +0.009 | +1.2% | $0.756 | $0.786 | $0.731 | 6,277,700 | |
| $0.746 | -0.059 | -7.3% | $0.820 | $0.834 | $0.730 | 5,840,500 | |
| $0.805 | -0.025 | -3.0% | $0.830 | $0.840 | $0.801 | 3,587,600 | |
| $0.830 | -0.062 | -7.0% | $0.881 | $0.893 | $0.820 | 4,231,000 | |
| $0.892 | +0.106 | +13.5% | $0.820 | $0.936 | $0.802 | 3,801,600 | |
| $0.786 | +0.010 | +1.3% | $0.790 | $0.817 | $0.771 | 4,383,700 | |
| $0.776 | -0.021 | -2.6% | $0.782 | $0.815 | $0.770 | 1,896,700 | |
| $0.797 | -0.029 | -3.5% | $0.818 | $0.822 | $0.783 | 1,906,100 | |
| $0.826 | 0.000 | 0.0% | $0.849 | $0.863 | $0.810 | 2,088,700 | |
| $0.826 | -0.009 | -1.1% | $0.820 | $0.827 | $0.790 | 1,960,300 | |
| $0.835 | +0.031 | +3.9% | $0.835 | $0.847 | $0.803 | 2,576,600 | |
| $0.804 | -0.076 | -8.6% | $0.869 | $0.880 | $0.780 | 4,988,000 | |
| $0.880 | -0.075 | -7.9% | $0.860 | $0.901 | $0.753 | 12,570,200 | |
| $0.955 | -0.010 | -1.0% | $0.996 | $1.010 | $0.942 | 3,495,200 | |
| $0.965 | +0.065 | +7.2% | $0.910 | $0.970 | $0.894 | 3,630,400 | |
| $0.900 | -0.002 | -0.2% | $0.900 | $0.916 | $0.879 | 1,718,900 | |
| $0.902 | -0.037 | -3.9% | $0.923 | $0.923 | $0.843 | 3,627,200 | |
| $0.939 | -0.004 | -0.4% | $0.926 | $0.980 | $0.922 | 2,851,300 | |
| $0.943 | -0.054 | -5.4% | $0.970 | $0.975 | $0.910 | 4,052,500 | |
| $0.997 | +0.046 | +4.8% | $0.945 | $1.030 | $0.866 | 5,426,100 | |
| $0.951 | -0.009 | -0.9% | $1.015 | $1.050 | $0.934 | 8,550,800 |
- Ticker
- NASDAQ:IVVD
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 16, 2026
Invivyd Reports Third Quarter 2026 Financial Results and Recent Business Highlights
Latest earnings call · May 14, 2026
Invivyd (NASDAQ:IVVD) Q1 2026 Earnings Call
Replay and transcript
Latest deck · Sep 29, 2026
Corporate Update (September 2026)
Corporate update · 23 slides
Latest news
Invivyd Reports Third Quarter 2026 Financial Results and Recent Business Highlights
Nov 16, 2026
Closed $0.538 (-7.6%) on Nov 16, 2026
Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Nov 3, 2026
Closed $0.582 (-0.1%) on Nov 3, 2026
Invivyd Presents VMS063, a Potential Best-in-Class Monoclonal Antibody Candidate for the Treatment and Prevention of Measles, at IDWeek 2026
Oct 21, 2026
Closed $0.639 (+0.4%) on Oct 21, 2026
Invivyd Announces Positive Topline Results from LIBERTY Phase 3 Study Demonstrating VYD2311 Safety and Tolerability Superior to mRNA-based COVID-19 Vaccine; Announces Regulatory Submission Plans for VYD2311
Sep 29, 2026
Closed $0.85 (-10.5%) on Sep 29, 2026
Invivyd to Participate in Upcoming September Investor Conferences
Sep 8, 2026
Closed $0.826 (0.0%) on Sep 8, 2026
Invivyd Reports Inducement Grants under Nasdaq Listing Rule 5635(4)
Sep 4, 2026
Closed $0.826 (-1.1%) on Sep 4, 2026
Invivyd Appoints Chairman Marc W. Elia as Chief Executive Officer; Approaches Results of VYD2311 studies DECLARATION and LIBERTY
Sep 1, 2026
Closed $0.88 (-7.9%) on Sep 1, 2026
Invivyd Reports Second Quarter 2026 Financial Results and Recent Business Highlights
Aug 13, 2026
Closed $0.721 (+5.1%) on Aug 14, 2026
Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - August 4, 2026
Aug 5, 2026
Closed $0.604 (+5.4%) on Aug 5, 2026
Invivyd, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 36 in the last 12 months · 138 in all · newest Nov 16, 2026 · oldest 2022
- Calls
- 12 calls with a replay · 12 with a transcript · latest May 14, 2026
- Decks
- 29 decks · latest Sep 29, 2026
Where Invivyd, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:IVVD · Home listing · This page | NASDAQ | United States | USD |
| BOATS:IVVD | BOATS | United States | USD |
Valuation
EV/sales 0.1× against a median of 2.1×: 4th lowest of 8 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $3.86M USD
- P/E
- Loss
- EV/sales
- 0.1×
- EV/EBITDA
- Negative EBITDA
- Price/book
- 0.8×
- Gross margin
- 91.8%
- Operating margin
- −224.4%
- Net margin
- −214.8%
- Debt to equity
- 0.1×
- Beta vs S&P 500
- 2.06
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Invivyd, Inc. · NASDAQ:IVVD | US$122.0M | US$3.86M | n/a | 0.1× | n/a | 0.8× | −214.8% | 0.1× | 2.06 |
| MacroGenics, Inc. · NASDAQ:MGNX | US$125.3M | −US$127.6M | n/a | −0.9× | n/a | 5.0× | −34.6% | 1.4× | 0.83 |
| PolyPid Ltd. · NASDAQ:PYPD | US$124.3M | US$119.3M | n/a | n/a | n/a | 23.1× | n/a | 0.3× | 0.93 |
| Compass Therapeutics, Inc. · NASDAQ:CMPX | US$123.9M | −US$29.89M | n/a | n/a | n/a | 0.9× | n/a | 0.1× | 1.22 |
| Humacyte, Inc. · NASDAQ:HUMA | US$123.7M | US$96.01M | n/a | 40.1× | n/a | 6.8× | n/a | 2.0× | 2.56 |
| Biomm SA · BMFBOVESPA:BIOM3 | US$122.6M | US$136.5M | 18.4× | 2.1× | 12.3× | 2.2× | 10.3% | 0.3× | n/a |
| Satellos Bioscience Inc · TSX:MSCL | US$121.9M | US$69.23M | n/a | n/a | n/a | 2.5× | n/a | 0.0× | 0.49 |
| Alar Pharmaceuticals Inc · TPEX:6785 | US$121.0M | US$51.66M | n/a | 568× | n/a | 1.7× | n/a | 0.0× | n/a |
| CANbridge Pharmaceuticals Inc. · HKEX:1228 | US$120.4M | US$111.5M | n/a | 13.3× | n/a | n/a | −146.4% | n/a | n/a |
| Atrium Therapeutics, Inc. · NASDAQ:RNA | US$118.4M | −US$113.0M | n/a | −2.9× | n/a | 0.6× | −229.7% | 0.0× | 0.76 |
| Adagene, Inc. · NASDAQ:ADAG | US$118.2M | −US$3.65M | n/a | −0.5× | n/a | 1.1× | −229.6% | 0.1× | 1.43 |
| Median of the others | US$122.3M | US$60.45M | 18.4× | 2.1× | 12.3× | 2.2× | −146.4% | 0.1× | 0.93 |
Forecasts
3 strong buy · Analysts' consensus from EODHD, read Nov 18, 2026. Not 6ix's view and not investment advice.
- Price target
- 10.00 USD · Analysts' mean
- EPS, year to Dec 2026
- -0.57 · 1 analyst
- Revenue, year to Dec 2026
- 60.33M · 3 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Marc Elia | Chairman of the Board and Chief Executive Officer |
| William Duke | Chief Financial Officer |
| Jill Andersen | Chief Legal Officer & Corporate Secretary |
| Rachael Gerlach | Senior Vice President of Regulatory Affairs |
| Julie Green | Chief Human Resources Officer |
| Michael Mina | Chief Medical Officer and Chief Epidemiologist |
| Robert Allen | Chief Scientific Officer |
| Timothy Lee | Chief Commercial Officer |
Board
| Director | Role |
|---|---|
| Marc Elia | Chairman of the Board and Chief Executive Officer |
| Ajay Royan | Lead Independent Director |
| Ian Sheffield | Director |
| Kevin F. McLaughlin | Director |
| Paul B. Bolno | Director |
| Tamsin Berry | Director |
| Terrance McGuire | Director |
Events
Calls
| Call | When | Status |
|---|---|---|
| Invivyd (NASDAQ:IVVD) Q1 2026 Earnings Call | Thu, May 14, 2026 · 8:30 AM ET | Replay |
| Invivyd (NASDAQ:IVVD) Q4 2025 Earnings Call | Thu, Mar 05, 2026 · 8:30 AM ET | Replay |
| Invivyd (NASDAQ:IVVD) Q3 2025 Earnings Call | Thu, Nov 06, 2025 · 8:30 AM ET | Replay |
| Invivyd (NASDAQ:IVVD) Q1 2025 Earnings Call | Thu, May 15, 2025 · 8:30 AM ET | Replay |
| Invivyd (NASDAQ:IVVD) Q3 2024 Earnings Call | Thu, Nov 14, 2024 · 8:30 AM ET | Replay |
| Invivyd (NASDAQ:IVVD) Q2 2024 Earnings Call | Wed, Aug 14, 2024 · 8:30 AM ET | Replay |
| Invivyd (NASDAQ:IVVD) Q1 2024 Earnings Call | Thu, May 09, 2024 · 4:30 PM ET | Replay |
| Invivyd (NASDAQ:IVVD) Q3 2023 Earnings Call | Thu, Nov 09, 2023 · 4:30 PM ET | Replay |
| Invivyd (NASDAQ:IVVD) Q2 2023 Earnings Call | Thu, Aug 10, 2023 · 4:30 PM ET | Replay |
| Invivyd (NASDAQ:IVVD) Q1 2023 Earnings Call | Thu, May 11, 2023 · 4:30 PM ET | Replay |
All 12 calls
| Call | When | Status |
|---|---|---|
| Invivyd (NASDAQ:IVVD) Q4 2022 Earnings Call | Thu, Mar 23, 2023 · 4:30 PM ET | Replay |
| Invivyd (NASDAQ:IVVD) Q3 2022 Earnings Call | Thu, Nov 10, 2022 · 4:30 PM ET | Replay |
Results days
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 16, 2026 · Before open | −7.6% |
| Q2 2026 | Aug 13, 2026 · After close | +5.1% |
| Q1 2026 | May 14, 2026 · Before open | −21.1% |
| Q4 2025 | Mar 26, 2026 | −12.2% |
| Q3 2025 | Nov 6, 2025 · Before open | +1.3% |
| Q2 2025 | Aug 14, 2025 · After close | −11.5% |
| Q1 2025 | May 15, 2025 · Before open | −15.8% |
| Q4 2024 | Mar 26, 2025 · Before open | −6.7% |
| Q3 2024 | Nov 14, 2024 · Before open | −11.2% |
| Q2 2024 | Aug 14, 2024 · Before open | −7.5% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 9, 2024 · After close | −6.6% |
| Q4 2023 | Mar 28, 2024 · Before open | +11.0% |
| Q3 2023 | Nov 9, 2023 · After close | 0.0% |
| Q2 2023 | Aug 10, 2023 · After close | +3.2% |
| Q1 2023 | May 11, 2023 · After close | +0.7% |
| Q4 2022 | Mar 23, 2023 · After close | −8.4% |
| Q3 2022 | Nov 10, 2022 · After close | +1.1% |
| Q2 2022 | Aug 15, 2022 · Before open | 0.0% |
| Q1 2022 | May 13, 2022 · Before open | +2.3% |
| Q4 2021 | Mar 30, 2022 · Before open | +30.4% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Corporate Update (September 2026) | Corporate update | 23 slides | Sep 29, 2026 |
| Q1 2026 Earnings Presentation | Earnings | 25 slides | May 14, 2026 |
| Corporate Update (April 2026) | Corporate update | 19 slides | Apr 9, 2026 |
| Q4 2025 Earnings Presentation | Earnings | 17 slides | Mar 5, 2026 |
| World Vaccine Congress Washington 2026 | Conference | 29 slides | March 2026 |
| Investor Presentation (January 2026) | Investor deck | 31 slides | Jan 8, 2026 |
| Q3 2025 Earnings Presentation | Earnings | 23 slides | Nov 6, 2025 |
| Investor Presentation (October 2025) | Investor deck | 38 slides | Oct 30, 2025 |
| Investor Presentation (August 2025) | Investor deck | 24 slides | Aug 14, 2025 |
| Q1 2025 Earnings Presentation | Earnings | 39 slides | May 15, 2025 |
All 29 decks
Financings
| Raise | Date |
|---|---|
| Public offering of common stock and pre-funded warrants Announced: about US$125M · US$2.5 a share · Cantor +1 Dealers: Cantor (lead), H.C. Wainwright & Co. Use of proceeds: Commercial preparedness for potential VYD2311 launch, R&D on RSV and measles programs, SPEAR Study Group efforts, working capital and general corporate purposes | Nov 18, 2025 |
| At-the-market programme of at-the-market (ATM) offering facility Closed: US$29.8M raised | Nov 6, 2025 |
| Public offering of common stock and pre-funded warrants Closed: US$57.5M raised · US$0.52 a share · Cantor Dealers: Cantor (lead) Buyers: RA Capital Management; Janus Henderson Investors Use of proceeds: VYD2311 clinical program, RSV and measles pipeline R&D, SPEAR Study Group efforts, working capital and general corporate purposes | Aug 22, 2025 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Went public as Adagio Therapeutics, Inc. Priced at US$17.00 a share on Aug 5, 2021.
- Price
- US$17.00 a share
- Shares offered
- 18,200,000 shares of common stock
- Offering size
- US$309.4 million
- Underwriters' option
- Up to 2,730,000 more shares
- Underwriters
- MORGAN STANLEY, JEFFERIES, STIFEL, GUGGENHEIM SECURITIES · In the order on the cover
- Shares delivered
- On or about Aug 10, 2021
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | May 21, 2021 |
| Filed publicly | Jul 16, 2021 |
| Amended twice | Newest Aug 4, 2021 |
| Shares registered with an exchange | Aug 3, 2021 |
| Declared effective by the SEC | Aug 5, 2021 |
| Final prospectus, with the price | Aug 6, 2021 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Aug 6, 2021 |
| EFFECT · Notice that a registration is effective | Aug 5, 2021 |
| S-1MEF · Registration of more shares for the same offering | Aug 5, 2021 |
| CERT · Exchange's certificate of listing | Aug 5, 2021 |
| S-1/A · Registration statement, amended | Aug 4, 2021 |
| CORRESP · Letter to the SEC | Aug 3, 2021 |
| CORRESP · Letter to the SEC | Aug 3, 2021 |
| CORRESP · Letter to the SEC | Aug 3, 2021 |
| UPLOAD · Letter from the SEC | Aug 3, 2021 |
| 8-A12B · Registration of shares for listing on an exchange | Aug 3, 2021 |
All 21 filings
| Filing | Filed |
|---|---|
| CORRESP · Letter to the SEC | Aug 2, 2021 |
| S-1/A · Registration statement, amended | Aug 2, 2021 |
| UPLOAD · Letter from the SEC | Jul 26, 2021 |
| CORRESP · Letter to the SEC | Jul 16, 2021 |
| S-1 · Registration statement | Jul 16, 2021 |
| DRS/A · Draft registration statement, amended | Jul 13, 2021 |
| UPLOAD · Letter from the SEC | Jul 8, 2021 |
| DRSLTR · Letter to the SEC with a draft | Jun 28, 2021 |
| DRS/A · Draft registration statement, amended | Jun 28, 2021 |
| UPLOAD · Letter from the SEC | Jun 16, 2021 |
| DRS · Draft registration statement | May 21, 2021 |
Open IPO · From the cover of the final prospectus (424B4) filed Aug 6, 2021
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2021 | FY2021 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 53.4M | 25.4M | 0 | 0 | 0 | ||||
| Cost of revenue | 3.75M | 1.62M | 2.03M | 462.0K | 1.00K | ||||
| Gross profit | 49.7M | 23.8M | -2.03M | -462.0K | -1.00K | ||||
| Research and development | 38.3M | 137.3M | 158.7M | 179.2M | 182.9M | 106.5M | |||
| Selling, general and administrative | 66.9M | 63.4M | 49.1M | 47.0M | 36.5M | ||||
| Operating income | -55.6M | -176.9M | -212.8M | -248.0M | -226.9M | -112.0M | |||
| Depreciation and amortization | 2.11M | 3.11M | 480.0K | 41.0K | 1.00K | 43.2M | |||
| EBITDA | -53.5M | -173.8M | -212.3M | -248.0M | -226.9M | -68.8M | |||
| Interest expense | 43.1M | 15.0M | |||||||
| Income before tax | -52.5M | -169.9M | -198.6M | -241.3M | -226.8M | -112.0M | |||
| Income tax | 0 | 0 | 0 | 0 | 0 | -43.2K | |||
| Net income | -52.5M | -169.9M | -198.6M | -241.3M | -226.8M | -143.7M | -83.4M | -38.7M | -112.0M |
| Earnings per share, basic | -0.30 | -1.43 | -1.81 | -2.23 | -5.32 | -1.29 | -14.89 | -1.01 | |
| Earnings per share, diluted | -0.30 | -1.43 | -1.81 | -2.23 | -5.32 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2021 | FY2021 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 226.7M | 69.3M | 200.6M | 92.1M | 542.2M | 478.3M | 392.5M | 91.2M | 115.0M |
| Short-term investments | 0 | 279.9M | 49.2M | 0 | |||||
| Receivables | 13.9M | 10.9M | 0 | 377.0K | 229.0K | ||||
| Inventory | 25.5M | 25.9M | 0 | -377.0K | -229.0K | ||||
| Current assets | 247.5M | 100.7M | 224.9M | 376.9M | 616.7M | 680.2M | 396.1M | 117.4M | |
| Property, plant and equipment | 1.36M | 1.51M | 1.90M | 2.28M | 83.0K | ||||
| Total assets | 276.9M | 129.5M | 229.2M | 383.2M | 620.1M | 686.3M | 398.0M | 117.4M | |
| Accounts payable | 13.7M | 10.4M | 7.95M | 1.52M | 5.78M | 17.6M | 10.7M | 8.15M | |
| Current liabilities | 34.2M | 62.0M | 50.3M | 25.0M | 62.1M | 53.0M | 37.9M | 13.1M | |
| Total debt | 2.49M | 1.30M | 2.17M | 3.72M | |||||
| Total liabilities | 35.3M | 62.0M | 51.7M | 27.2M | 62.1M | 53.1M | 37.9M | 182.6M | |
| Shareholders' equity | 241.5M | 67.5M | 177.5M | 356.0M | 558.0M | 633.2M | -144.6M | -103.4M | -65.2M |
| Shares outstanding | 282.0M | 119.8M | 110.2M | 109.0M | 110.8M | 111.3M | 5.60M | 0 | 111.2M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Cash from operations | -58.1M | -170.5M | -173.2M | -220.0M | -184.7M | -14.6M |
| Capital spending | -155.0K | -140.0K | -615.0K | -1.71M | -84.0K | -84.0K |
| Free cash flow | -58.3M | -170.6M | -173.8M | -221.7M | -184.8M | -14.6M |
| Cash from investing | -155.0K | -140.0K | 280.7M | -230.7M | -50.7M | -50.7M |
| Cash from financing | 215.6M | 39.3M | 1.04M | 506.0K | 662.7M | 129.6M |
| Share buybacks | -633.0K | 0 | -1.00K | -4.00K | 0 | -3.00K |
| Change in cash | 157.3M | -131.3M | 108.6M | -450.1M | 427.2M | 115.0M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 16, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 16, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 16, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 16, 2026 | Results | SEC |
| 8-K · Current report | Sep 29, 2026 | Current report | SEC |
| 4 · Change in ownership | Sep 2, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Sep 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 1, 2026 | Insider trade | SEC |
| 8-K · Current report | Sep 1, 2026 | Management or board change | SEC |
| 4 · Change in ownership | Aug 18, 2026 | Insider trade | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Aug 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 18, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 17, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 17, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 17, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 17, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 17, 2026 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Aug 13, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 13, 2026 | Results | SEC |
| 4 · Change in ownership | Aug 4, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Aug 4, 2026 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Jul 28, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Jul 24, 2026 | Current report | SEC |
| 8-K · Current report | Jul 6, 2026 | Current report | SEC |
| 4 · Change in ownership | May 21, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 21, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 21, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 21, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 21, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 21, 2026 | Insider trade | SEC |
| 8-K · Current report | May 19, 2026 | Meeting outcome | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2026 | Big-stake notice | SEC |
| S-8 · Registration statement for employee plans | May 14, 2026 | Offer document | SEC |
| 10-Q · Quarterly report | May 14, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 14, 2026 | Results | SEC |
| 8-K · Current report | Apr 9, 2026 | Current report | SEC |
| ARS · Annual report to shareholders | Apr 6, 2026 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 6, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 6, 2026 | Meeting notice | SEC |
| 10-K · Annual report | Mar 5, 2026 | Annual report | SEC |
| 8-K · Current report | Mar 5, 2026 | Results | SEC |
| 4 · Change in ownership | Feb 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 18, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Feb 17, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 17, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 17, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 17, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 17, 2026 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 17, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 17, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 17, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 13, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 12, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 30, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 30, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 30, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 30, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 30, 2026 | Insider trade | SEC |
| 8-K · Current report | Jan 8, 2026 | Results | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Dec 29, 2025 | Big-stake notice | SEC |
| EFFECT · Notice that a registration is effective | Dec 29, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 23, 2025 | Other filings | SEC |
| 8-K · Current report | Dec 23, 2025 | Current report | SEC |
| CORRESP · Letter to the SEC | Dec 19, 2025 | Other filings | SEC |
| S-3/A · Registration statement, amended | Dec 19, 2025 | Offer document | SEC |
| SCHEDULE 13G · Big-stake notice | Nov 25, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Nov 24, 2025 | Current report | SEC |
| 4 · Change in ownership | Nov 20, 2025 | Insider trade | SEC |
| 8-K · Current report | Nov 19, 2025 | Material contract | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Nov 19, 2025 | Big-stake notice | SEC |
| 424B5 · Prospectus | Nov 18, 2025 | Offer document | SEC |
| FWP · Free writing prospectus | Nov 17, 2025 | Offer document | SEC |
| 144 · Notice of proposed sale | Nov 17, 2025 | Other filings | SEC |
| 424B5 · Prospectus | Nov 17, 2025 | Offer document | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Nov 12, 2025 | Big-stake notice | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Nov 7, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 6, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 6, 2025 | Results | SEC |
| 8-K · Current report | Oct 30, 2025 | Current report | SEC |
| SCHEDULE 13G · Big-stake notice | Oct 22, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Oct 14, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Oct 6, 2025 | Current report | SEC |
| S-3 · Registration statement | Oct 2, 2025 | Offer document | SEC |
| 4 · Change in ownership | Sep 24, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Sep 24, 2025 | Insider trade | SEC |
| 8-K · Current report | Sep 24, 2025 | Management or board change | SEC |
| SCHEDULE 13G · Big-stake notice | Sep 8, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 29, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 27, 2025 | Big-stake notice | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Aug 26, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Aug 22, 2025 | Material contract | SEC |
| 424B5 · Prospectus | Aug 22, 2025 | Offer document | SEC |
| FWP · Free writing prospectus | Aug 20, 2025 | Offer document | SEC |
| 424B5 · Prospectus | Aug 20, 2025 | Offer document | SEC |
| 4 · Change in ownership | Aug 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 19, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 18, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 18, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 18, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 18, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 18, 2025 | Other filings | SEC |
| 10-Q · Quarterly report | Aug 14, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 14, 2025 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Jul 2, 2025 | Current report | SEC |
| 8-K · Current report | Jun 26, 2025 | Current report | SEC |
| 4 · Change in ownership | May 22, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 22, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 22, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 22, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 22, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 22, 2025 | Insider trade | SEC |
| 8-K · Current report | May 20, 2025 | Meeting outcome | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | May 15, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 15, 2025 | Results | SEC |
| 8-K · Current report | May 12, 2025 | Current report | SEC |
| 8-K · Current report | Apr 25, 2025 | Current report | SEC |
| 8-K · Current report | Apr 21, 2025 | Material contract | SEC |
| ARS · Annual report to shareholders | Apr 7, 2025 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 7, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 7, 2025 | Meeting notice | SEC |
| 4 · Change in ownership | Mar 26, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Mar 26, 2025 | Insider trade | SEC |
| 8-K · Current report | Mar 26, 2025 | Management or board change | SEC |
| 10-K · Annual report | Mar 20, 2025 | Annual report | SEC |
| 8-K · Current report | Mar 20, 2025 | Results | SEC |
| 8-K · Current report | Mar 5, 2025 | Current report | SEC |
| 8-K · Current report | Feb 24, 2025 | Current report | SEC |
| 4 · Change in ownership | Feb 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 19, 2025 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 12, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Feb 3, 2025 | Results | SEC |
| 8-K · Current report | Jan 27, 2025 | Current report | SEC |
| 8-K · Current report | Jan 10, 2025 | Current report | SEC |
| 4 · Change in ownership | Dec 31, 2024 | Insider trade | SEC |
| 8-K · Current report | Dec 27, 2024 | Current report | SEC |
| 4 · Change in ownership | Dec 26, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Dec 20, 2024 | Other filings | SEC |
| 4 · Change in ownership | Dec 19, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 16, 2024 | Insider trade | SEC |
| SC 13D/A · Big-stake notice, amended | Dec 12, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Dec 11, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Dec 9, 2024 | Other filings | SEC |
| 8-K · Current report | Dec 2, 2024 | Management or board change | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 14, 2024 | Quarterly report | SEC |
| 8-K · Current report | Nov 14, 2024 | Results | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 12, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 8, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Oct 29, 2024 | Results | SEC |
| 8-K · Current report | Sep 23, 2024 | Current report | SEC |
| 8-K · Current report | Sep 6, 2024 | Current report | SEC |
| 8-K · Current report | Sep 4, 2024 | Current report | SEC |
| 8-K · Current report | Sep 3, 2024 | Current report | SEC |
| 8-K · Current report | Aug 27, 2024 | Current report | SEC |
| 10-Q · Quarterly report | Aug 14, 2024 | Quarterly report | SEC |
| 8-K · Current report | Aug 14, 2024 | Results | SEC |
| 8-K · Current report | Jun 14, 2024 | Current report | SEC |
| 4 · Change in ownership | Jun 6, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jun 6, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 31, 2024 | Insider trade | SEC |
| 8-K · Current report | May 31, 2024 | Management or board change | SEC |
| 144 · Notice of proposed sale | May 29, 2024 | Other filings | SEC |
| 4 · Change in ownership | May 23, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 23, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 23, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 23, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 23, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 23, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | May 23, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 23, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | May 23, 2024 | Insider trade | SEC |
| 8-K · Current report | May 22, 2024 | Meeting outcome | SEC |
| 144 · Notice of proposed sale | May 16, 2024 | Other filings | SEC |
| S-8 · Registration statement for employee plans | May 9, 2024 | Offer document | SEC |
| 10-Q · Quarterly report | May 9, 2024 | Quarterly report | SEC |
| 8-K · Current report | May 9, 2024 | Results | SEC |
| 8-K · Current report | May 7, 2024 | Current report | SEC |
| EFFECT · Notice that a registration is effective | Apr 22, 2024 | Other filings | SEC |
| ARS · Annual report to shareholders | Apr 18, 2024 | Annual report | SEC |
| CORRESP · Letter to the SEC | Apr 18, 2024 | Other filings | SEC |
This page holds 200 of 452 filings. Open Filings
Cap table
Built by 6ix from Invivyd, Inc.’s releases · as of Oct 29, 2026
- Common shares
- 295,632,147
- Fully diluted
- 295,632,147
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 295,632,147 | Oct 29, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Oct 29, 2026 | 295,632,147 |
| Sep 30, 2026 | 295,632,147 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Michael Wyzga Other companies: Tvardi Therapeutics, Inc. (Board Member · Since at least Apr 15, 2025); Mereo BioPharma Group plc (Chairman of the Board · Since at least Jan 1, 2024); X4 Pharmaceuticals, Inc. (Director · Since at least Mar 13, 2019); Kineta Inc. (See Remarks · Aug 16, 2021 – Dec 2, 2022 · Past); LogicBio Therapeutics Inc (Director · Oct 18, 2018 – Nov 16, 2022 · Past); EXACT Sciences Corporation (Director · Feb 9, 2015 – Feb 26, 2021 · Past); Akebia Therapeutics, Inc. (Director · Mar 19, 2014 – Jun 14, 2018 · Past); OncoMed Pharmaceuticals Inc (Director · Oct 14, 2013 – Jun 22, 2018 · Past); Idenix Pharmaceuticals Inc (Director · Mar 1, 2012 – Aug 5, 2014 · Past); Radius Health, Inc. (Chief Executive Officer, Director · Dec 5, 2011 – Dec 15, 2011 · Past); Genzyme Corp (Executive VP and CFO · May 25, 2006 – Apr 4, 2011 · Past) | Director · Aug 5, 2021 – May 23, 2023 · Past |
| Frederick W. Driscoll Other companies: Lite Strategy, Inc. (Chairperson, Non-Executive Director · Since at least Feb 22, 2018); Cellectar Biosciences, Inc. (Director · Since at least Apr 10, 2017); ConforMIS Inc (INTERIM CFO & INTERIM TREAS · Oct 23, 2019 – Oct 23, 2019 · Past); Cue Biopharma, Inc. (Director · Jun 26, 2018 – Jan 2, 2025 · Past); ImmunityBio, Inc. (Director · Sep 18, 2017 – Aug 11, 2020 · Past); Flexion Therapeutics Inc (Chief Financial Officer · Feb 11, 2014 – Nov 19, 2021 · Past); Oncotelic Therapeutics Inc (Director · Jan 1, 2014 – Jun 1, 2016 · Past); Novavax, Inc. (VP, CFO & Treasurer · Aug 24, 2009 – Mar 2, 2013 · Past); Genelabs Technologies Inc (CEO/PRESIDENT · Nov 1, 2007 – Jan 7, 2009 · Past) | Interim CFO · Oct 13, 2022 – Oct 13, 2022 · Past |
| Terrance McGuire Other companies: Tectonic Therapeutic, Inc. (Director · Since at least Jun 20, 2024); Seer, Inc. (Director · Since at least Dec 3, 2020); Cyclerion Therapeutics, Inc. (Director · Apr 1, 2019 – Nov 30, 2023 · Past); Alector, Inc. (Director · Feb 6, 2019 – Sep 11, 2023 · Past); X4 Pharmaceuticals, Inc. (Director · Nov 15, 2017 – Jun 5, 2018 · Past); Pulmatrix, Inc. (Director · Jun 15, 2015 – May 16, 2019 · Past); Trevena, Inc. (Director · Jan 30, 2014 – May 14, 2014 · Past); Acceleron Pharma Inc (Director · Sep 18, 2013 – Mar 2, 2017 · Past); Ironwood Pharmaceuticals, Inc. (Director · Jun 3, 2013 – Apr 1, 2019 · Past) | Director · Since at least Aug 5, 2021 |
| Jane Pritchett Henderson Other companies: CARGO Therapeutics, Inc. (Director · Since at least Jun 3, 2024); Apogee Therapeutics, Inc. (Chief Financial Officer · Since at least Jul 13, 2023); Akero Therapeutics Inc (Director · Since at least Jun 19, 2019); Sesen Bio Inc (Director · Jun 12, 2018 – May 3, 2021 · Past); IVERIC bio Inc (Director · Jan 13, 2018 – Jul 11, 2023 · Past); Voyager Therapeutics, Inc. (Sr. V.P. & CFO, Corp. Dev. · Jan 1, 2017 – Mar 22, 2018 · Past); Eleven Biotherapeutics Inc (Director · Feb 5, 2014 – May 19, 2017 · Past) | Chief Financial Officer · Aug 5, 2021 – Jan 30, 2022 · Past |
| Clive Meanwell Other companies: Metsera, Inc. (EXECUTIVE CHAIRMAN, Director · Since at least Jan 30, 2025); Fractyl Health, Inc. (Executive Chairman and Founder of Population Health Partners · Since at least Feb 1, 2024); EQRx Inc (Director · Dec 17, 2021 – Nov 9, 2023 · Past); Population Health Investment Co Inc (Chief Executive Officer, Director · Nov 17, 2020 – Aug 24, 2021 · Past); The Medicines Company (Chief Innovation Officer, Director · Jul 1, 2015 – Jan 6, 2020 · Past) | Director · Jun 22, 2022 – May 23, 2023 · Past |
| Tomas J. Heyman Other companies: Legend Biotech Corp. (Director · Since at least Mar 18, 2026); Exelixis, Inc. (Director · Since at least May 31, 2023); Akero Therapeutics Inc (Director · Since at least Jun 9, 2020); Xilio Therapeutics, Inc. (Director · Sep 15, 2022 – Jun 12, 2023 · Past); OptiNose (Director · Dec 1, 2020 – May 21, 2025 · Past) | Director · Aug 5, 2021 – May 23, 2023 · Past |
| Kevin F. McLaughlin Other companies: Vericel Corporation (Director · Since at least Jan 6, 2015); Decibel Therapeutics Inc (Director · Oct 10, 2022 – Sep 25, 2023 · Past); Acceleron Pharma Inc (SVP, CFO and Treasurer · Jul 7, 2015 – Nov 19, 2021 · Past) | Director · Since at least May 21, 2024 |
| William Duke Other companies: Apexigen Inc. (Chief Financial Officer · Jul 29, 2022 – Aug 23, 2023 · Past); Kaleido Biosciences, Inc. (Chief Financial Officer · Nov 22, 2019 – Jan 14, 2022 · Past); Pulmatrix, Inc. (Chief Financial Officer · Jun 24, 2015 – May 16, 2019 · Past) | Chief Financial Officer · Since at least Sep 1, 2023 |
| Howard Mayer Other companies: PepGen Inc. (Non-Executive Director · Since at least Nov 10, 2023); Entasis Therapeutics Holdings Inc (Director · Aug 5, 2019 – Jul 7, 2022 · Past) | Director · Aug 5, 2021 – Jun 22, 2022 · Past |
| Ian Sheffield Other companies: Fractyl Health, Inc. (Director · Since at least Sep 2, 2025); Apyx Medical Corporation (Director · Dec 13, 2013 – May 6, 2015 · Past) | Director · Since at least Aug 30, 2026 |
All 36 people
| Person | Seat |
|---|---|
| René Russo Other companies: Xilio Therapeutics, Inc. (President and Chief Executive Officer · Since at least Oct 21, 2021); X4 Pharmaceuticals, Inc. (Director · Jun 17, 2019 – Jun 2, 2021 · Past) | Director · Aug 5, 2021 – Aug 5, 2021 · Past |
| Tillman U Gerngross Other companies: Alector, Inc. (Director · Feb 6, 2019 – Jun 14, 2023 · Past); X4 Pharmaceuticals, Inc. (Director · Nov 15, 2017 – Jun 5, 2018 · Past) | Chief Executive Officer, Director · Aug 5, 2021 – Jan 30, 2022 · Past |
| Ajay Royan Other companies: Fractyl Health, Inc. (Director · Since at least Feb 1, 2024) | Lead Independent Director · Since at least Aug 5, 2021 |
| Marc Elia Other companies: Fractyl Health, Inc. (Founder of M28 Capital, Inc. · Since at least Feb 1, 2024) | Chairman of the Board and Chief Executive Officer · Since at least May 23, 2023 |
| Michael Mina Other companies: Quantum-Si Incorporated (Director · Jun 10, 2021 – May 12, 2023 · Past) | Chief Medical Officer and Chief Epidemiologist · Since Mar 5, 2026 |
| Paul B. Bolno Other companies: Wave Life Sciences Ltd. (President and Chief Executive Officer · Since at least Nov 10, 2015) | Director · Since at least Sep 22, 2025 |
| Rebecca Dabora Other companies: Apogee Therapeutics, Inc. (Chief Development Officer · Since at least Nov 4, 2026) | Chief Tech and Manuf Officer · Aug 5, 2021 – Dec 14, 2022 · Past |
| Redonda Miller Other companies: Cencora, Inc. (Director · Since at least Jan 1, 2023) | Director · Nov 19, 2021 – Jun 22, 2022 · Past |
| Srishti Gupta Other companies: NovaBridge Biosciences (Chief Executive Officer and Director · Since at least Jul 1, 2026) | Director · May 21, 2024 – May 21, 2024 · Past |
| Anand Shah | Director · Aug 5, 2021 – Aug 5, 2021 · Past |
| Christine Lindenboom | Director · Oct 20, 2022 – May 20, 2025 · Past |
| David Hering | Chief Executive Officer, Director · Aug 5, 2021 – Dec 18, 2023 · Past |
| Elham Hershberger | Chief Development Officer · Aug 5, 2021 – Jan 30, 2022 · Past |
| Ellen R Marram | Director · Nov 19, 2021 – Nov 19, 2021 · Past |
| Jeremy Gowler | COO & CCO · Dec 18, 2023 – Dec 18, 2023 · Past |
| Jill Andersen | Chief Legal Officer & Corporate Secretary · Since at least Nov 1, 2021 |
| Julie Green | Chief Human Resources Officer · Since at least Jan 24, 2024 |
| Lynn Connolly | Chief Medical Officer · Aug 5, 2021 – Jan 30, 2022 · Past |
| Peter Schmidt | Chief Medical Officer · Dec 6, 2022 – Dec 18, 2023 · Past |
| Rachael Gerlach | Senior Vice President of Regulatory Affairs · Since at least Feb 3, 2026 |
| Robert Allen | Chief Scientific Officer · Since at least May 14, 2026 |
| Robert D Allen III | Chief Scientific Officer · Since at least Apr 11, 2023 |
| Sara Cotter | Director · Jul 25, 2023 – May 21, 2024 · Past |
| Stacy Price | Chief Tech. and Manuf. Officer · Mar 27, 2023 – Dec 18, 2023 · Past |
| Tamsin Berry | Director · Since at least Jun 22, 2022 |
| Timothy Lee | Chief Commercial Officer · Since at least Jun 5, 2024 |
Log in to ask 6ix AI your own questions about Invivyd, Inc.